Author

R. Rath

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

O. Shriwas· 4 shared R. Dash· 4 shared S. Mohanty· 4 shared P. Mohapatra· 3 shared R. Arya· 2 shared S. A. Ansari· 2 shared S. K. Das Majumdar· 2 shared S. R. Kaushik· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

O. Shriwas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CMTM6 mediates cisplatin resistance in OSCC by regulating AKT/c-MYC driven ribosome biogenesis

P. Mohapatra, S. Mohanty, S. A. Ansari, O. Shriwas, A. Ghosh, R. Rath, S. K. Das Majumdar, R. K. Swain, S. K. Raghav, R. Dash

This study identifies CMTM6 as a regulator of ribosome biogenesis in cisplatin-resistant OSCC, showing that targeting this pathway can restore chemosensitivity.

bioRxiv · Apr 8, 2022 · PreprintCancer Biology

CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis

S. Mohanty, P. Mohapatra, O. Shriwas, M. Priyadarshini, S. A. Ansari, S. Priyadarsini, R. Rath, M. Sultania, S. K. Das Majumdar, R. Dash

The paper identifies MINK1 as a key driver of 5FU resistance in OSCC using CRISPR screening and shows that lestaurtinib can restore 5FU sensitivity.

bioRxiv · Aug 19, 2021Cancer Biology

CMTM6 drives cisplatin resistance in OSCC by regulating AKT mediated Wnt signaling

P. Mohapatra, O. Shriwas, S. Mohanty, S. R. Kaushik, R. Arya, R. Rath, S. Das Majumdar, D. Muduly, R. K. Nanda, R. Dash

This study identifies CMTM6 as a driver of cisplatin resistance in OSCC by activating AKT-mediated Wnt signaling, leading to increased survival gene expression and tumor growth.

bioRxiv · Mar 18, 2020Cancer Biology

RRBP1 rewires cisplatin resistance in Oral Squamous Cell Carcinoma by regulating YAP-1

O. Shriwas, R. Arya, S. Mohanty, S. Kumar, R. Rath, S. R. Kaushik, M. C. Thakur, F. Pahwa, S. K. D. Majumdar, D. K. Muduly, R. Nanda, R. Dash

This study identifies RRBP1 as a key regulator of cisplatin resistance in OSCC, showing its role in YAP-1 regulation and demonstrating that Radezolid can restore cisplatin sensitivity.

bioRxiv · Mar 18, 2020Cancer Biology